Company Filing History:
1 out of 512 
1 out of 8 Years Active: 2025
Title: The Innovative Contributions of Makoto Fushimi
Introduction
Makoto Fushimi is a notable inventor based in Harrison, NY (US). He has made significant strides in the field of cancer therapy through his innovative research and development of targeted drug delivery systems. His work focuses on the advancement of PI3K inhibitors, which play a crucial role in treating various proliferative diseases, including cancer.
Latest Patents
Fushimi holds a patent for "PI3K inhibitors and uses thereof." This patent outlines the development of a new, targeted drug delivery paradigm that is coupled with improved PI3K inhibitors, specifically PI3Kα inhibitors. The patent details various compounds, including those of Formula (I) and (II), along with their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs. These compounds are designed to be effective in the treatment and prevention of diseases such as cancer. Additionally, the patent describes nanoparticles and nanogels that encapsulate these compounds for targeted delivery to cancer cells or tumors.
Career Highlights
Throughout his career, Fushimi has worked with prestigious organizations, including the Sloan Kettering Institute for Cancer Research and the Tri-Institutional Therapeutics Discovery Institute. His contributions to cancer research have been instrumental in developing new therapeutic strategies that enhance the efficacy of treatments.
Collaborations
Fushimi has collaborated with esteemed colleagues in the field, including Maurizio Scaltriti and Daniel Alan Heller. These partnerships have further enriched his research and have led to advancements in cancer therapy.
Conclusion
Makoto Fushimi's innovative work in developing PI3K inhibitors and targeted drug delivery systems represents a significant advancement in cancer treatment. His contributions continue to impact the field of oncology and offer hope for improved therapeutic options for patients.